September is Blood Cancer Awareness monthNeoGenomics stands by the fighters, survivors and caregivers of those with leukemia, lymphoma, and myeloma.Our Company Overview Investor Relations CareersPharma ServicesNeoGenomics offers lab services for oncology clinical trialsLearn moreCOVID-19Precision Medicine during this CrisisClick here to viewDONATE YOUR PLASMALatest Presented: September 2, 2020 Source: Webinar Launching a Companion Diagnostic Research & Development Through Commercialization Learn More Presented: August 19, 2020 Source: Webinar The Role of Liquid Biopsy Testing in Lung Cancer An overview of testing options for patients with NSCLC Learn More Image Published: August 11, 2020 Source: Article Is It Validated? NeoGenomics has a menu of >600 assays across many different technologies and approaches. Clients… Learn More Published: July 28, 2020 Source: Press Release NeoGenomics Reports Revenue of $87 Million in the Second Quarter amid COVID-19 Pandemic Learn More Published: July 20, 2020 Source: Press Release NeoGenomics Announces Board Appointments Learn More New Tests Image Available: September 2, 2020 Methodology: Immunohistochemistry (IHC) DLL3 Delta-like protein 3 (DLL3) expression is regulated by ASCL1, a transcription factor that is… Learn More Image Available: August 4, 2020 Methodology: FISH, Molecular NeoTYPE® Follicular Lymphoma Profile The NeoTYPE® Follicular Lymphoma Profile analyzes 15 genes through a combination of next-generation… Learn More Image Available: August 4, 2020 Methodology: FISH, Molecular NeoTYPE® Follicular Lymphoma Profile The NeoTYPE® Follicular Lymphoma Profile analyzes 15 genes through a combination of next-generation… Learn More Image Available: July 13, 2020 Methodology: FISH PDGFB Rearrangement (22q13) Probe(s): PDGFB (22q13.1) Disease(s): Dermatofibrosarcoma protuberans (DFSP) Learn More Image Available: July 13, 2020 Methodology: FISH MYC Amplification for Angiosarcoma Probes: MYC (8q24) | Centromere 8 Disease(s): Angiosarcoma Learn More
